Terminal exon definition occurs cotranscriptionally and promotes termination of RNA polymerase II. NLM AIDSLINE Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Terminal exon definition occurs cotranscriptionally and promotes termination of RNA polymerase II.

Mol Cell. 1999 Mar;3(3):371-8. Unique Identifier : AIDSLINE MED/99214852
Dye MJ; Proudfoot NJ; Sir William Dunn School of Pathology, University of Oxford,; United Kingdom.

Abstract: Analysis of nascent transcription from the human epsilon- and beta-globin genes shows that transcriptional termination occurs within 1.5 kb of the poly(A) site and is dependent on the presence of functional poly(A) signals. Even so, transcripts that have not been cleaved at the poly(A) site are detected up to the termination region, suggesting that there is a kinetic lag between transcription over the poly(A) signal and its effect on transcriptional termination. Surprisingly, mutation of the splice acceptor (SA) of the beta-globin IVS2 also abolishes transcriptional termination. Our results emphasize the interconnection of transcription and RNA processing by showing that the enhancement of 3' end processing by the terminal splice acceptor occurs cotranscriptionally.
Keywords: JOURNAL ARTICLE Cell Nucleus/GENETICS/METABOLISM Codon, Terminator/*GENETICS DNA, Recombinant/GENETICS Exons/*GENETICS Globin/GENETICS Hela Cells Human HIV Long Terminal Repeat/GENETICS Introns/GENETICS Kinetics Models, Genetic Mutation Nucleic Acid Hybridization Poly A/GENETICS Promoter Regions (Genetics)/GENETICS Response Elements/GENETICS RNA Polymerase II/*METABOLISM RNA, Messenger/ANALYSIS/BIOSYNTHESIS/*METABOLISM Support, Non-U.S. Gov't Transcription, Genetic/*GENETICS TransfectionKWDjournalarticlecellnucleus/genetics/metabolismcodon,terminator/KWDgeneticsdna,recombinant/geneticsexons/
990730
A9971152

Copyright © 1999 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .